Dow Up0.51% Nasdaq Up0.24%

Bristol-Myers Squibb Company (BMY)

58.80 Up 0.19(0.32%) Nov 21, 4:05PM EST
|After Hours : 58.80 0.00 (0.00%) Nov 21, 4:20PM EST
ProfileGet Profile for:
Bristol-Myers Squibb Company
345 Park Avenue
New York, NY 10154
United States - Map
Phone: 212-546-4000
Fax: 212-546-4020

Index Membership:N/A
Industry:Drug Manufacturers - Major
Full Time Employees:28,000

Business Summary 

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company’s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliance with OliPass Corporation to discover and develop therapeutics against various targets using OliPass' technology platform. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Bristol-Myers Squibb Company

Corporate Governance 
Bristol-Myers Squibb Company’s ISS Governance QuickScore as of Nov 1, 2014 is 7. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 4; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Lamberto Andreotti , 63
Chief Exec. Officer, Director, Member of Exec. Committee and Member of Securities Issuance Committee
Mr. Charles A. Bancroft , 54
Chief Financial Officer and Exec. VP
Mr. Giovanni Caforio M.D., 49
Chief Operating Officer and Director
Dr. Francis M. Cuss MB BChir, FRCP, 59
Chief Scientific Officer, Exec. VP and Member of Science & Technology Committee
Ms. Sandra Leung , 53
Gen. Counsel and Corp. Sec.
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders